Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Seelos Therapeutics Inc (SEEL)  
$0.11 0.00 (0.00%) as of 4:30 Mon 11/27


Download
   
Exchange: Nasdaq Small Cap
Security Type: Common
Shares Out: 102,230,000
Market Cap: 10.87(M)
Last Volume: 10,264,973 Avg Vol: 10,237,079
52 Week Range: $0.1063 - $1.64
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. Co. is also developing several preclinical programs, including SLS-004, SLS-006, and SLS-007 for the potential treatment of Parkinson's Disease, SLS-010 in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 158,757 158,757
Total Buy Value $0 $0 $200,222 $200,222
Total People Bought 0 0 2 2
Total Buy Transactions 0 0 2 2
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 395
  Page 7 of 16  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-04-09 4 A $0.00 $0 D/D 100,000 2,221,760     -
   Liu Vivian H Executive Vice President   •       •      –    2010-04-01 5 GD $0.00 $0 D/D 3,000 257,427     -
   Berman Richard J Director   –       •      –    2010-03-31 4 A $0.31 $10,000 D/D 32,680 339,841     -
   Crea Roberto Director   –       •      –    2010-03-31 4 A $0.31 $10,000 D/D 32,680 125,167     -
   Ray Rusty Director   –       •      –    2010-03-31 4 A $0.31 $10,000 D/D 32,680 32,680     -
   Oppenheim Leonard A Director   –       •      –    2010-03-31 4 A $0.31 $10,000 D/D 32,680 244,824     -
   Crea Roberto Director   –       •      –    2010-03-15 4 A $0.17 $10,556 D/D 62,832 92,487     -
   Damaj Bassam President and CEO   •       •      –    2010-03-15 4 A $0.17 $211,117 I/I 1,256,650 1,849,740     -
   Damaj Bassam President and CEO   •       •      –    2010-03-15 4 A $0.17 $500,767 D/D 2,980,755 4,387,559     -
   Cox Edward M. VP of Corp. Development   •       –      –    2010-03-15 4 A $0.17 $54,487 D/D 324,327 477,396     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-03-15 4 A $0.17 $124,187 I/I 739,206 1,088,082     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-03-15 4 A $0.17 $242,164 D/D 1,441,451 2,121,760     -
   Berman Richard J Director   –       •      –    2010-03-09 4 S $0.50 $30,937 D/D (61,873) 307,161     -
   Crea Roberto Director   –       •      –    2010-01-11 4 A $0.17 $1,719 D/D 10,233 29,655     -
   Cox Edward M. VP of Corp. Development   •       –      –    2010-01-11 4 A $0.17 $8,874 D/D 52,819 153,069     -
   Damaj Bassam Chief Executive Officer   •       •      –    2010-01-11 4 A $0.17 $34,382 I/I 204,657 593,090     -
   Damaj Bassam Chief Executive Officer   •       •      –    2010-01-11 4 A $0.17 $81,554 D/D 485,443 1,406,804     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-01-11 4 A $0.17 $20,225 I/I 120,386 348,876     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2010-01-11 4 A $0.17 $39,439 D/D 234,753 680,309     -
   Oppenheim Leonard A Director   –       •      –    2009-12-16 4 S $0.42 $63,418 D/D (150,707) 212,144     -
   Cox Edward M. VP of Corp. Development and IR   •       –      –    2009-12-14 3 IO $0.00 $0 D/D 0 100,250     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2009-12-14 3 IO $0.00 $0 I/I 0 228,490     -
   Esber Henry Jemil EVP Pre-Clinical Business Dev.   •       •      –    2009-12-14 3 IO $0.00 $0 D/D 0 445,556     -
   Crea Roberto Director   –       •      –    2009-12-14 3 IO $0.00 $0 D/D 0 19,422     -
   Damaj Bassam Chief Executive OfficerOfficer   •       •      –    2009-12-14 3 IO $0.00 $0 I/I 0 388,433     -
  395 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 16
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us